“…In both cases, a method to identify the effectiveness of a drug is vital, and the ability to streamline the screening into a robust, reliable, high-throughput process is necessary. There are several assays available commercially and/or for research purposes from simple live-dead assays and surface apoptosis markers such as Annexin-V, to cytosolic monitoring of apoptosis through caspase reporter biomarkers (Carpenter et al, 2006;Gelles & Chipuk, 2016;Helmy & Azim, 2012;Lamprecht, Sabatini, & Carpenter, 2007;Saraste & Pulkki, 2000;Saraste, 1999;Xiao, Gibbons, Luker, & Luker, 2015;Ziraldo, Link, Abrams, & Ma, 2014. Most apoptosis assays are end-point assays lacking abilities to report dynamic drug responses temporally and intracellular spatially.…”